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Background: Past studies have shown that mean values of Interleukin-6 (IL-6) and C-reactive protein (CRP) do not
change significantly in COPD patients over a one-year period. However, longer period follow-up studies are still
lacking. Thus, the aim of this study is to evaluate plasma CRP and IL-6 concentration over three years in COPD
patients and to test the association between these inflammatory mediators and disease outcome markers.
Methods: A cohort of 77 outpatients with stable COPD was evaluated at baseline, and 53 (mean FEV1, 56%
predicted) were included in the prospective study. We evaluated Interleukin-6 (IL-6), C-reactive protein (CRP),
six-minute walking distance (6MWD), and body mass index (BMI) at baseline and after three years. Plasma
concentration of IL-6 was measured by high sensitivity ELISA, and CRP was obtained by high sensitivity
particle-enhanced immunonephelometry.
Results: IL-6 increased significantly after 3 years compared to baseline measurements [0.8 (0.5-1.3) vs 2.4 (1.3-4.4)
pg/ml; p < 0.001] and was associated with worse 6MWD performance. In the Cox regression, increased IL-6 at
baseline was associated with mortality [Hazard Ratio (95% CI) = 2.68 (0.13, 1.84); p = 0.02]. CRP mean values did not
change [5 (1.6-7.9) vs 4.7 (1.7-10) pg/L; p = 0.84], although eleven patients (21%) presented with changes >3 mg/L
in CRP after 3 years.
Conclusions: The systemic inflammatory process, evaluated by IL-6, seems to be persistent, progressive and
associated with mortality and worse physical performance in COPD patients.
Trial registration: No.: NCT00605540
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Chronic obstructive pulmonary disease (COPD) affects
primarily the lungs; however, it is now recognized as a
disease with systemic repercussions, and it is associated
with chronic inflammation [1]. In fact, there is increas-
ing evidence that systemic inflammatory mediators such
as C-reactive protein (CRP) and interleukin 6 (IL-6) are
increased in the peripheral blood of COPD patients
[2,3]. Cross-sectional studies show that CRP levels are
related to important clinical outcomes, including exer-
cise tolerance [4], health status [5] and the exacerbation
of disease [6]. Plasma IL-6 concentration is known as a* Correspondence: renataferrarifisio@gmail.com
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reproduction in any medium, provided the orpowerful promoter of CRP production in the liver [7],
and it is associated with CRP levels in COPD patients
[4,5,8]. IL-6 levels also have been shown to interfere with
malnutrition pathophysiology since is increased in low
weight COPD patients [9]. A previous study has shown
that mean values of CRP remained stable over a 17-
month period [10]; in addition, Kolsum et al. [8] have
shown that IL-6 did not change over one-year.
Recent study showed that systemic inflammation,
when present for at least 1 year, was associated with a
higher incidence of exacerbations and worse survival
despite similar lung impairment in COPD patients [11].
Furthermore, survival analyses show that the addition of
white blood cell counts and the systemic levels of IL-6,
CRP, interleukin 8, fibrinogen, chemokine ligand 18, andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clinical variables to predict mortality in COPD patients
[12]. In a cohort of 253 COPD patients, the results
showed that the highest levels of inflammatory markers
was related to the degree of airflow obstruction, func-
tional capacity and health status [13]. The importance of
studies to evaluate the inflammatory status in COPD has
increased since the launching of new drugs, such as an
oralphosphodiesterase 4 (PDE4) inhibitor with systemic
effects and appears to offer the potential to target the in-
flammatory processes underlying COPD [14]. Clinical
trials have demonstrated that roflumilast improves lung
function and reduces exacerbation frequency in COPD.
In summary, systemic inflammation in COPD is
associated with poor outcomes and long-term follow-up
studies of inflammatory mediators are needed to bet-
ter understand the progression of this outcome. We
hypothesized that reporting the evolution of CRP and
IL-6 will provide information regarding the utility of
these mediators in clinical practice and consequently to
guide therapeutic interventions in COPD. Thus, the aim
of this study was to evaluate plasma CRP and IL-6 con-
centration over three years in COPD patients and to test
the association between these inflammatory media-




Seventy-seven patients with mild to very severe COPD
attending the Botucatu Medical School in Brazil were
evaluated, and 53 participated in the prospective study.
Major inclusion criteria included a diagnosis of COPD
according to GOLD 2006 and the Brazilian Thoracic
Society (BTS) guidelines [1,15]. Exclusion criteria
included a primary diagnosis of other respiratory
diseases or chronic diseases, recent (<4 months) myocar-
dial infarction, unstable angina or congestive heart fail-
ure (New York Heart Association class III or IV).
Patients not clinically stable (changes in medication, dis-
ease exacerbation, or hospital admissions in the preced-
ing 6 weeks) were also excluded. Patients were evaluated
at baseline and were interviewed by telephone every 3 -
months to identify data associated with exacerbation
and/or hospitalizations (see the Additional file 1). The
study was approved by the Research Ethics Committee
of Botucatu Medical School University Hospital (390/
2007), and all patients signed an informed consent.
Measurements
Spirometry and pulse oximeter oxygen saturation (SpO2)
Pre and post bronchodilator spirometry was performed
(Ferrari KOKO Louisville, CO 80027, USA) according to
criteria set by the American Thoracic Society [16]. SpO2was assessed using an Onyx oxymeter (Model 9500
Oximeter; Nonin Medical Inc.; Minneapolis, MN, USA)
on room air.
Blood sampling and analysis
Fasting peripheral blood was collected (08.00 hours),
and plasma was stored at −80°C. IL-6 was assessed in
duplicate by high sensitivity commercial kits using en-
zyme linked immunosorbent assay (ELISA) according to
the manufacturer's instructions (BioSource International
Inc, Ca, USA) with a lower detection limit of 0.16 pg/
mL. CRP was assessed in duplicate by high sensitivity
particle enhanced immunonephelometry (Cardio-Phase,
Dade Behring Marburg GmbH, Marburg, USA) with a
lower detection limit of 0.007 mg/L. All measurements
were performed after the final evaluation using kits of
the same lot number to avoid measurement bias.
Exercise tolerance
The six-minute walk distance (6MWD) was performed
according to the guidelines of the American Thoracic
Society [17] (see the Additional file 1).
Nutritional status, dyspnea perception, multidimensional
index, comorbidity index
Body weight and height were measured, and body mass
index [BMI = weight in kg/(height in m)2] was calculated.
Dyspnea was assessed using a translated version of the
Modified Medical Research Council (MMRC) scale [18].
BODE index was calculated using the model described
by Celli et al. [19]. Comorbidities were quantified by the
Charlson index [20].
Statistical analysis
All analyses were performed using SigmaStat 3.2 (Inc,
Chicago, IL, USA) and R statistical software [21].
Multivariate Cox regression analysis was performed to
evaluate the predictors of mortality including all the
subjects evaluated at baseline, adjusting for age, gender,
BODE index, SpO2 and comorbidity index. Paired
t-test or Wilcoxon test was performed to com-
pare characteristics at baseline and after three years. For
baseline characteristics, the unpaired t-test or the
Mann–Whitney test was used. Spearman correlations
were used to determine the relationships between in-
flammatory mediators. Two multiple linear regression
analyses were performed including gender, age, FEV1,
IL-6 and Charlson index, at baseline, as independent
variables and the baseline and final values of 6MWD as
the dependent variables. The same model was used with
BMI and number of exacerbations as the depen-
dent variables. A p ≤ 0.05 was defined as statistically
significant.
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The baseline characteristics of the 77 patients (66% men;
FEV1 = 57%) were mean age of 64 ± 9 years and smoking
exposure of 51 ± 29 pack-years; 24 patients (31%) were
active smokers. Sixty-five patients were using long-term
bronchodilators, and 17 patients were regularly using
inhaled corticosteroids; 16 had been on stable oxygen
flow therapy for the last six months. Comparison be-
tween patients using or not inhaled corticosteroids at
baseline and after three years showed no significant dif-
ference for the studied variables. No patients were
medicated with theophylline or leukotriene modifiers.
Of the 77 patients initially evaluated, 24 were excluded
from the final analyses; 11 patients died and 13 dropped
out (Figure 1). The causes of deaths were pulmonary
complications resulting from COPD in 4 patients, car-
diovascular disease in 5 patients, splenic abscess/septic
shock in one patient, and colon cancer in one patient.
Thus, 53 patients were monitored for three years.
At baseline, the mean age of the 53 patients included
in the prospective study (66% men) was 63 ± 9 years
with smoking exposure of 48 ± 27 pack-years; 16 patients
(30%) were active smokers. Eight patients (15%) were in
GOLD stage I, 19 (36%) were in stage II, 11 (20%) were
in stage III, and 15 (28%) were in stage IV COPD. There
was no difference in the proportion of patients within
each disease severity between baseline and after three
years (p = 0.99). The comparison of 53 patients’ charac-
teristics between baseline and after three years is shown
in Table 1 and has been included in a previous publica-
tion with 95 patients [22].
In summary, the FEV1 and FVC values, in liters, de-
cline statistically during the study period. There were
significant deteriorations of SpO2, MMRC, 6MWD, and
BODE index. The Charlson index increased significantly
in the period (3.0 ± 1.1 vs. 3.4 ± 1.2, p = 0.02). However,
in 14 patients, the increase was attributable only to the
change in the patient age. Forty-one patients (77.3%)
had at least one exacerbation during the study period
and in 10 patients (18.8%), the exacerbations were
severe.Figure 1 Diagram of patient follow up in three-year period.
6MWD= six-minute walking distance.Comparisons of characteristics of excluded patients
(n = 24) versus those completing the study (n = 53) are
shown in Table 2. Plasma IL-6 concentration was signifi-
cantly higher in the group of excluded patients (n = 24).
Sub-group analysis showed no statistical difference in
IL-6 values of dropouts (n = 13) versus those completing
the study (n = 53). However, patients who died (n = 11)
presented with significantly higher values of plasma IL-6
concentration when compared to studied patients
(n = 53) [1.5 (1.1 to 2.4) vs 0.8 (0.5 to 1.3) pg/ml, p =
0.031]. We found no differences in studied variables be-
tween the group of dropouts and patients who died. In
addition, the Cox regression including all patients (77)
showed that increased IL-6 at baseline was associated
with mortality [Hazard Ratio (95% CI) = 2.68 (0.13, 1.84);
p = 0.02] after adjustments for age, gender, BODE index,
SpO2 and comorbidity index.
IL-6 mean values increased significantly after 3 years
compared to baseline measurements [0.8 (0.5-1.3) vs 2.4
(1.3-4.4) pg/ml; p < 0.001]. Thirty-five patients (66%) had
increase > 1 pg/ml of IL-6 over three years. CRP mean
values did not change [5 (1.6-7.9) vs 4.7 (1.7-10) pg/L;
p = 0.84], although eleven patients (21%) presented with
changes in CRP >3 mg/L after 3 years (Figure 2). IL-6
was positively correlated with CRP at baseline (r = 0.54;
p < 0.001) and after a three-year period (r = 0.53;
p < 0.001). No influence of smoking in IL-6 levels was
found at baseline and after three years (data not shown).
In the multiple linear regression analysis, male gender
was associated with 6MWD values at baseline. Values of
IL-6 and FEV1, at baseline, were associated with walking
capacity at both moments, baseline and after three years
(Table 3). There were no associations between
inflammatory mediators and BMI and between inflam-
matory mediators and number of exacerbations. We
found no association between CRP and the other studied
variables.
Discussion
To our knowledge, the present study is the first one to
show increase over time in systemic inflammation, as
measured by plasma IL-6 concentration, in COPD
patients. Similar to previous studies [8,10], our results
showed that CRP mean values did not change. Further-
more, increased IL-6 levels were associated with mortal-
ity and also with reduced exercise tolerance at baseline
and after three years. Therefore, our three-year follow-
up study showed that IL-6 could be part of the assess-
ment of COPD progression, and increases in serum
values are markers of poorer outcomes.
COPD is characterized by a specific pattern of inflam-
mation involving increased numbers of CD8+ T lym-
phocytes, neutrophils and macrophages in small and
large airways and in lung parenchyma and pulmonary
Table 1 Characteristics of COPD patients followed for a three-year period
Variables Initial assessment (n = 53) Final assessment (n = 53) p-value
FEV1 (%) 56.0 ± 21.1 56.0 ± 22.6 0,48
FEV1 (l) 1.4 ± 0.7 1.3 ± 0.6 0.03
FVC (%) 88.9 ± 20.9 86.3 ± 24.3 0.20
FVC (l) 2.6 ± 0.9 2.5 ± 0.9 0.01
FEV1/FVC 50.5 ± 12.1 50.2 ± 10.6 0.49
SpO2 (%) 93.0 ± 3.1 91.6 ± 4.9 0.02
MMRC (score) 1.6 ± 1.0 2.0 ± 1.2 0.01
6MWD (m) 444.0 ± 82.8 406.3 ± 102.9 <0.001
BMI (kg/m2) 25.6 ± 5.5 25.5 ± 5.4 0.38
BODE index 2.4 ± 1.9 2.9 ± 2.5 0.01
Comparisons of patient characteristics at baseline and after three years were performed by Paired t-test or Wilcoxon; p ≤ 0.05. Values are presented as mean ± SD.
Definition of abbreviations: FEV1 = forced expiratory volume in the first second (% of predicted); FVC = forced vital capacity (% of predicted); SpO2 = pulse
oximeter oxygen saturation; MMRC = Modified Medical Research Council; 6MWD = six-minute walking distance; BMI = body mass index.
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in orchestrating this inflammation through the release
of inflammatory cytokines, such as IL-6, that attract
neutrophils into the airways. IL-6 regulates many
pathways that could contribute to its effect on inflam-
matory disease progression. During CD4 T cell differen-
tiation, IL-6 promotes IL-17 and IL-21 production, and
suppresses regulatory T cell function. The down-
stream effect of IL-6 is deposition of matrix, antibody
complexes and proteases in the targeted tissue and, con-
sequently, tissue destruction [23]. However, given the
cross-sectional nature of most studies, the role of IL-6
over time is not clear. Kolsum et al. [8] showed that the
IL-6 mean values did not change significantly during the
one-year period, and there was moderate repeatability of
IL-6 between the two visits. By contrast, our results
reported that IL-6 mean values increased significantlyTable 2 Comparison of baseline characteristics of the exclude
Variables Excluded patients (n = 24)
Gender F/M (n) 8/16
Age (years) 65.5 ± 9.3
FEV1 (%) 61.3 ± 30.0
FVC (%) 94.7 ± 28.9
FEV1/FVC 50.7 ± 13.7
SpO2 (%) 92.9 ± 4.9
MMRC (score) 1.6 ± 1.0
6MWD (m) 406.9 ± 105.7
BMI (kg/m2) 24.9 ± 5.4
IL-6 (pg/ml) 1.4 ± 1.0
CRP (mg/L) 9.7 ± 12.5
Comparisons between excluded patients and those completing the study were per
values are presented as mean ± SD. Other values are presented as numbers. Definit
expiratory volume in the first second (% of predicted); FVC = forced vital capacity (%
saturation; MMRC =Modified Medical Research Council; 6MWD = six-minute walking
C-reactive protein.after three years compared to baseline measurements.
We also found that patients who died presented higher
plasma IL-6 concentration when compared to survivors.
Furthermore, increased IL-6 at baseline was associated
with mortality after adjustments for age, gender, BODE
index, SpO2 and comorbidity index. Association between
serum IL-6 and prognosis is not conclusive considering
the results of recent studies [24,25]. Mehrotra et al. [24]
showed that IL-6 was a significant predictor of mortality
in 268 elderly subjects with obstructive airway disease.
Another study [12] showed association between mortal-
ity and levels of WBC counts, IL-6, fibrinogen, CCL-18,
CRP, IL-8, and SP-D in 1843 COPD patients studied
over three years. Using C statistics, only IL-6 independ-
ently added predictive power to the basic clinical model;
however, the addition of all the biomarkers in the panel
significantly increased the ability of clinical variables tod patients versus those completing the study
Studied patients (n = 53) p-value
18/35 0.84
62.9 ± 8.9 0.23
56.0 ± 21.1 0.65
88.9 ± 20.9 0.35
50.5 ± 12.1 0.84
93.0 ± 3.1 0.49
1.6 ± 1.0 0.96
444.0 ± 82.8 0.10
25.6 ± 5.5 0.62
0.9 ± 0.7 0.04
8.0 ± 11.8 0.42
formed using the unpaired t-test or Mann–Whitney test; p ≤ 0.05. Plus–minus
ion of abbreviations: Gender F/M = gender female/male; FEV1 = forced
of predicted); BMI = body mass index; SpO2 = pulse oximeter oxygen
distance; BMI = body mass index; IL-6 = Interleukin 6; CRP =
Figure 2 Plasma concentration of IL-6 and CRP at baseline and after three years. IL-6 = Interleukin 6; CRP = C-reactive protein. Data show
medians with interquartile range.
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Waschki et al. [25] did not find an association between
mortality and levels of IL-6 in 170 outpatients with
stable COPD.
CRP mean values did not change over time, although
21% of the patients presented with >3 mg/L changes in
CRP after 3 years. We also found no association between
CRP levels and mortality or differences in outcome
variables between patients who survived at least 3 years
with and without increases in CRP >3 mg/L (data not
shown). In line with our findings, de Torres et al. [26]
showed that baseline serum CRP did not correlate with
mortality in patients with moderate to very severe
COPD after a three year follow up study. In addition,
Pinto-Plata et al. [10] also reported that CRP mean level
did not change over a 17-month interval. In contrast,
epidemiologic studies showed an association between
baseline levels of systemic inflammatory markers and
COPD progression [27,28]. In a study with mild to
moderate COPD patients, baseline serum levels of CRP
were divided into quintiles. After five years of follow-up,
it was observed that the highest quintile of CRP was a
predictor of mortality compared with the lowest quintile
[27]. In the study by Dahl et al. [28], a baseline serumTable 3 Multiple linear regression models to evaluate the fac
Variables Baseline 6MWD p-va
Coefficient (95% CI)
Gender (Male) 48.36 (8.61, 88.10) 0.
Age (years) −1.40 (−4.77, 1.96) 0.4
FEV1 (%) 1.57 (0.74, 2.40) <0.
IL-6 (pg/ml) −42.02 (−65.49, -22.56) <0.
Charlson index −8.81 (−33.77, 16.18) 0.4
Baseline (R2 = 0.52; p ≤ 0.05) and after three years (R2 = 0.44; p ≤ 0.05). Definition of a
volume in the first second (% of predicted); IL-6 = Interleukin 6. For both regressionCRP greater than 3 mg/L was associated with increased
risk of hospitalization and death after 8 years of follow-
up in COPD patients.
As reported in previous studies, we found that CRP
levels were positively correlated with plasma IL-6 con-
centration [4,5,8]; however, while IL-6 levels increased,
mean values of CRP did not change over time. Biologic-
ally, IL-6 is a primary cytokine regulator of CRP in the
liver [7] and may play a salient role in the systemic in-
flammatory response in COPD [29]. IL-6 has been stud-
ied as a COPD marker, since it is increased in low weight
COPD patients [9], and its higher levels were associated
with lower levels of lung function independent of
confounders such as age and smoking [30]. It also plays a
critical role in hematopoiesis, causing thrombocytosis
and leukocytosis with IL-6 overexpression [31]. In
addition, studies have showed that serum IL-6 is a
powerful independent predictor of future cardiovascular
events in Japanese patients with multiple cardiovascular
risk factors [32] and in older adults from a 9-year cohort
[33], and the authors suggest that its prognostic value is
superior to that of CRP.
We also found that IL-6 was negatively correlated with
6MWD at baseline and after 3 years. Although wetors associated with baseline and final values of 6MWD
lue Final 6MWD p-value
Coefficient (95% CI)
02 22.64 (−26.55, 71.84) 0.35
0 −0.60 (−4.88, 3.66) 0.77
001 1.88 (0.82, 2.95) <0.001
001 −54.86 (−82.40, -27.32) <0.001
8 −11.52 (−43.31, 20.25) 0.46
bbreviations: 6MWD = six-minute walking distance; FEV1 = forced expiratory
analysis the variables values were those obtained at baseline.
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suggest a persistence deleterious effect of IL-6 on phys-
ical performance of COPD patients and further investi-
gation is warranted. In agreement with our results,
Brinkley et al. [34] found that IL-6 levels were associated
with poorer physical function, independent of age, gen-
der, race, and body composition in older adults across
multiple comorbidities, including COPD patients. Yende
at al. [35] also showed that IL-6 was an independent pre-
dictor of reduced exercise capacity in elderly individuals
with an obstructive pattern and with normal spirometry
results. In a cross-sectional analysis, Garrod et al. [5]
evaluated the values of TNF-α, IL6 and CRP in 41
patients with COPD and found a negative association be-
tween CRP and 6MWD, similar to other studies [4,10].
These results provide evidence that chronic inflamma-
tion and impaired physical function are related in various
age-related diseases. Our study, in line with this hypoth-
esis, shows that inflammation is persistent and associated
with exercise tolerance over time in COPD patients.
We also explored the relationship between number of
exacerbations and plasma IL-6 and CRP concentration;
however, no association was found. Agusti et al. [11]
showed that the annual rate of exacerbations during the
3 year follow-up were higher in the persistently inflamed
patients, compared with non-inflamed patients. How-
ever, the logistic regression did not show association
between that annual rate of exacerbations and the pres-
ence of persistent systemic inflammation (defined as in
upper quartile at baseline and after one-year for at least
2 biomarkers).
The strengths of this study are the wide range of dis-
ease severities designed to evaluate changes in systemic
inflammation and its relationship to disease prognosis
outcomes over a considerable period of time. Despite of
the small number of patients, this study shows the asso-
ciation of IL-6 with prognosis in COPD patients and
reinforces the role of this mediator in the evaluation of
patients’ outcomes. In addition, taking in consideration
the difference in values of serum IL-6 between healthy
subjects and smokers in previous study [3], a sample of
40 COPD patients would be necessary (α = 0.05; power
= 80%). However, a large sample size could allow the
identification of a reliable cutoff value of IL-6 to predict
poorer prognosis. We measured the systemic inflamma-
tory mediators at baseline and after three years; there-
fore our study has limitations regarding the predictor
value of serum IL-6 for shorter periods of time.
Conclusions
The systemic inflammatory process, evaluated by IL-6,
seems to be persistent and progressive in COPD
patients. In addition, increased systemic inflammation is
associated with mortality and with reduced exercisetolerance over time. These results suggest that inflam-
matory markers could contribute to evaluate outcomes
related to COPD progression.
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